晚期多个系统缩:与疾病进展缓慢相关的神经病理特征
Misato Ozawa1,2, Rie Saito1, Takuya Konno3,4
1Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Brain pathology (Zurich, Switzerland)
|May 19, 2025
概括
晚期发作的多系统缩 (LO-MSA) 显示神经退行不那么严重,并且可能比通常年龄发作的MSA (UO-MSA) 进展缓慢. 这表明LO-MSA可能具有与一般MSA病例相比的预后,如果得到适当的护理.
科学领域:
- 神经学 神经学
- 病理学 病理学 病理学
- 老年病的医生 老年病的医生
背景情况:
- 晚期多重系统缩 (LO-MSA),症状在75岁以上开始,比以前认为的更为普遍.
- LO-MSA的临床病理学特征尚不清楚,需要进一步研究.
研究的目的:
- 阐明晚发多系统缩 (LO-MSA) 的临床病理特征.
- 为了比较LO-MSA和通常年龄开始的MSA (UO-MSA) 之间的临床和病理差异.
主要方法:
- 对比了5名LO-MSA患者和24名UO-MSA患者 (疾病持续时间相似) 的临床和组织病理特征.
- 在排列黑色 (StrN) 和橄突脑 (OPC) 系统中评估退化的严重程度.
- 脑干自主核和脊柱中间侧核中的量化神经元数量.
- 测量了膜,下橄细胞核和腹侧髓 (VLM) 中的α-synuclein包含密度.
主要成果:
- 无论LO-MSA还是UO-MSA都主要显示MSA-olivopontocerebellar缩 (OPCA) 亚型.
- 与UO-MSA相比,LO-MSA表现出较少严重的StrN和OPC系统退化.
- LO-MSA对大脑干自主神经元,特别是VLM中的血清性神经元的保护更好 (p=0.013).
- LO-MSA显示,骨中的α-同核素含量密度显著降低 (p<0.001).
结论:
- 在LO-MSA中神经元退化似乎比在UO-MSA中进展得更慢.
- 对于LO-MSA的预后可能不会比MSA更糟糕,特别是如果有适当的医疗管理.
相关概念视频
Parkinson's Disease: Overview
399
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
399
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K


